Features of the course of polypous rhinosinusitis combined with allergic rhinitis

Both allergic rhinitis (AR) and polypous rhinosinusitis (PRS) are a serious problem in context of their impact on quality of life, the risk of complications, overlay of bronchial asthma (BA) and medical control of these diseases. In most cases, T2 type eosinophilic inflammation lies beneath their pathogenesis, but the mutual influence of simultaneously existing chronic processes on each other appears under-investigated. Objective of the study: Compare the clinical and immunological characteristics of patients with polypous rhinosinusitis and concomitant allergic rhinitis and without respiratory allergy. All patients with PRS were divided into 2 phenotypic groups: Group 1 – PRS without bronchial asthma and respiratory allergy (54 people), Group 2 - PRS + allergic rhinitis, but without bronchial asthma (46 people). IL-1β-, IL-4-, IL-5-, IL-6-, IL-13-, IFN-γ-, TGF-β1-, TGF-β2-, TGF β-3 cytokines in nasal polyp tissue were determined using the Bio-Plex multiplex analysis system. Results: In patients with PRS combined with AR, the eosinophilic type of inflammation in the polyp tissue was determined in 100% of cases, it was accompanied by an increased level of IL-6, TGF-β1, TGF-β2, TGF-β3 and a reduced level of IL-5, IL-13 compared to PRS without comorbid pathology. Conclusions. Given the same clinical course of polypous rhinosinusitis, the identification of the difference in the cytokine profile in the nasal polyp tissue gives evidence of a different mechanism of the inflammatory response for different phenotypes of PRS. The polypous rhinosinusitis combined with allergic rhinitis is characterized by 100% eosinophilic type of inflammation, high levels of TGF-β family protein cytokines, pro-inflammatory cytokine IL-6 and a lower level of T2-cytokines IL-5 and IL-13 compared with the PRS group without comorbid pathology. The simultaneous treatment of PRS and allergic rhinitis using the joint efforts of otorhinolaryngologists and allergists will allow to achieve medical monitoring of both diseases and prevent their progression and development of complications.

chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis, phenotypes, cytokines, diagnostic and treatment algorithms

1. Heffler E., Malvezzi L., Boita M., Brussino L., De Virgilio A., Ferrando M., et al. Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2018;14(9):731-737. doi: 10.1080/1744666X.2018.1512407.

2. McGarry G., Melia L. Nasal polyps: an update. Br J Hosp Med (Lond). 2009;70(9):500–504. doi: 10.12968/hmed.2009.70.9.43865.

3. Houser S.M., Keen K. The role of allergy and smoking in chronic rhinosinusitis and polyposis. Laryngoscope. 2008;118(9):1521–1527. doi: 10.1097/MLG.0b013e31817d01b8.

4. Fernández-Conde B.L., Soler R., Barasona M.J., Cantillo E., Moreno C., Guerra F. Allergenic profile of nasal polyposis. J Investig Allergol Clin Immunol. 2009;19(2):110-116. Available at: http://www.jiaci.org/issues/vol19issue2/3.pdf.

5. Asero R., Bottazzi G. Hypersensitivity to molds in patients with nasal polyposis: a clinical study. J Allergy Clin Immunol. 2000;(105):186– 188. doi: 10.1016/s0091-6749(00)90198-2.

6. Asero R., Bottazzi G. Nasal polyposis: a study of its association with airborne allergen hypersensitivity. Ann Allergy Asthma Immunol. 2001;86(3):283–285. doi: 10.1016/S10811206(10)63299-1.

7. Van Zele T., Gaevert P., Watelet J., Claeys G., Holtappels G., Claeys C., et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981–983. doi: 10.1016/j. jaci.2004.07.013.

8. Baturo A.P., Romanenko E.E., Leonova A.Iu., Iartseva A.S., Savlevich E.L., Mokronosova M.A. Domination of Staphylococcus aureus in microbiocenosis of nasal cavity in children and adults with infectious and allergic rhinitis. Zhurnal mikrobiologii, ehpidemiologii i immunobiologii = Journal of microbiology epidemiology immunobiology 2015;(1):72-74. (In Russ.) Available at: https://elibrary.ru/item. asp?id=25592671.

9. Erbek S.S., Erbek S., Topal O., Cakmak O. The role of allergy in the severity of nasal polyposis. Am J Rhinol. 2007;21(6):686–690. doi: 10.2500/ajr.2007.21.3062.

10. Bonfils P., Avan P., Malinvaud D. Influence of allergy on the symptoms and treatment of nasal polyposis. Acta Otolaryngol. 2006;126(8):839– 844. doi: 10.1080/00016480500504226.

11. Tokunaga T., Sakashita M., Haruna T., Asaka D., Takeno S., Ikeda H., et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70(8):995–1003. doi: 10.1111/all.12644.

12. Robinson S., Douglas R., Wormald P.J. The relationship between atopy and chronic rhinosinusitis. Am J Rhinol. 2006;20(6):625–628. doi: 10.2500/ajr.2006.20.2907.

13. Kirtsreesakul V. Role of allergy in the therapeutic response of nasal polyps. Asian Pac J Allergy Immunol. 2002;20(3):141–146. Available at: http://apjai-journal.org/wp-content/uploads/2018/02/1Roleofallergyinthether apeuticVol20No3September2002P141.pdf.

14. Kim J.W., Hong S.L., Kim Y.K., Lee C.H., Min Y.G., Rhee C.S. Histological and immunological features of non-eosinophilic nasal polyps. Otolaryngol Head Neck Surg. 2007;137(6):925– 930. doi: 10.1016/j.otohns.2007.07.036.

15. Annunziato F., Romagnani C., Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-635. doi: 10.1016/j. jaci.2014.11.001.

16. Kim D.W., Cho S.H. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res. 2017;9(4):299-306. doi: 10.4168/aair.2017.9.4.299.

17. Hulse K.E. Immune Mechanisms of Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2016;16(1):1. doi: 10.1007/s11882-015-0579-0.

18. Little S.C., Early S.B., Woodard C.R., Shonka D.C. Jr., Han J.K., Borish L., Steinke J.W. Dual action of TGF-beta1 on nasal-polyp derived fibroblasts. Laryngoscope. 2008;118(2):320-324. doi: 10.1097/MLG.0b013e318159cc0b.

19. Savlevich E.L., Kozlov V.S., Doroshchenko N.E., Zaseeva T.Y, Kubaeva L.M. Assessment of the diagnostic algorithm for allergic and nonallergic rhinitis using the database of Moscow outpatient units. Kremlin Medicine Journal. 2017;2(4):58-64. (In Russ.) Available at: https://elibrary.ru/download/elibrary_32400451_44136941.pdf.

20. Savlevich E.L., Kozlov V.S., Zharkikh M.A., Chernyshova D.A., Ruzakova E.A. Analysis of current therapeutic approaches to chronic rhinitis according to the polyclinic data of ambulatory service of Moscow. Medical Council. 2017;(16):60-67. (In Russ.) doi: 10.21518/2079701X-2017-16-60-67.

21. Peters A.T., Kato A., Zhang N., Conley D.B., Suh L., Tancowny B., et al. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2010;125(2):397–403. doi: 10.1016/j. jaci.2009.10.072.

22. Savlevich E.L., Dyneva M.E., Gaganov L.E., Egorov V.I., Gerasimov A.N., Kurbacheva O.M. Diagnostic and treatment algorithm for different phenotypes of chronic rhinosinusitis with nasal polyps. Russian Journal of allergy. 2019;16(2):50-60. (In Russ.) Available at: http:// rusalljournal.ru/wp-content/uploads/2019/07/ %D0%A0%D0%90%D0%96-%E2%84%96-22019-1-100-%D0%BF%D0%BE%D0%BB.-1.pdf.

23. Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., et al.; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476. doi: 10.1016/j. jaci.2010.06.047.

24. Ryazantsev S.V., Artyushkin S.A., Sosnovskaya D.V. The role and importance of antihistamines in the treatment of allergic rhinitis and urticarial. RMZH = RMJ. 2018;3(11):71-75. (In Russ.) Available at: https://www.rmj.ru/upload/ iblock/b42/71-75.pdf.

25. Belan E.B., Tibirkova E.V., Sadchikova T.L. Efficacy and safety of ebastine in allergic diseasese. Farmateka. 2018;(3):57-63. doi: 10.18565/pharmateca.2018.s3.57-62.